Centrexion Therapeutics
Trial Pipeline
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
NCT07122453
A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
NCT04154501
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
NCT03660943
A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis
NCT03576508
Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain
NCT02558439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Centrexion Therapeutics Shows
According to the ClinicalTrials.gov registry, Centrexion Therapeutics is linked to 33 US clinical trials across every stage of research activity. Of those, 29 studies are currently recruiting — about 88% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 12% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Centrexion Therapeutics reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 32 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Centrexion Therapeutics is Nociceptive Pain with 1 linked trial, and 6 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.